BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Core Insights - BrightInsight, in collaboration with Sanofi and Regeneron, has developed a Patient App aimed at improving adherence and persistence for a key biologic therapy, demonstrating a positive impact on patient engagement and treatment consistency [1][2][3] Industry Challenges - Adherence to self-injected therapies remains a significant challenge in the pharmaceutical industry, with adherence rates as low as 50% and a notable drop-off in persistence, where 35% to 63% of patients discontinue therapy within the first year [2] Product Impact - The Patient App has been adopted by over 25,000 patients, indicating its relevance and user-friendliness. Analysis of data from over 6,000 patients shows that users of the app have a 4% lower discontinuation rate and improved adherence after one year compared to non-users [2] Partnership Expansion - Based on positive user feedback and measurable results, Sanofi is expanding its partnership with BrightInsight into key international markets, leveraging the BrightInsight Platform for further development across its specialty care portfolio [3][4] Company Commitment - Sanofi is dedicated to enhancing the patient experience through scalable digital solutions, and the collaboration with BrightInsight has resulted in measurable improvements in therapy adherence and persistence [4] About BrightInsight - BrightInsight is recognized as a leading platform for compliant digital health solutions in the biopharma sector, assisting life sciences companies in digital transformation and providing technology to develop and scale digital solutions effectively [5]